title: Neutral endopeptidase protein expression and prognosis in localized prostate cancer.
abstract: OBJECTIVE
  Neutral endopeptidase (NEP) is a cell-surface peptidase that inactivates neuropeptide growth factors implicated in prostate cancer progression. The clinical significance of decreased NEP expression observed in prostate cancer is unclear. We investigated whether decreased NEP expression in localized prostate cancers is associated with prostate-specific antigen (PSA) relapse after radical prostatectomy.
  
  
  METHODS
  NEP expression patterns were examined by immunohistochemistry in 223 men, who underwent radical prostatectomy between 1990 and 2000 at the Veterans Administration Medical Center (New York, NY) with available representative tissues and adequate follow up. We also examined whether hypermethylation of the NEP promoter contributes to down-regulation of NEP protein expression in a subset of patients that showed decreased NEP expression (n = 22).
  
  
  RESULTS
  Three patterns of NEP expression were observed: (a) membranous expression similar to benign prostate epithelium (n = 82; 37%); (b) complete loss of NEP expression in prostate cancer compared with adjacent benign prostate glands (n = 105; 47%); and (c) heterogeneous NEP expression (n = 36; 16%). In a multivariate analysis, complete loss of NEP expression was associated with PSA relapse after controlling for grade, stage, pretreatment PSA, and race simultaneously (hazard ratio, 1.99; 95% confidence interval, 1.13-3.52; two-sided chi(2) P = 0.017). In addition, DNA hypermethylation of the NEP promoter was frequently (73%) identified in a subset of 22 of cases that showed decreased NEP expression.
  
  
  CONCLUSIONS
  Our data suggest that decreased NEP expression might contribute to progression of localized prostate cancer after surgery. Data also suggest that methylation is an important mechanism of NEP protein silencing. Larger prospective studies are required for confirmation.
authors.affiliation: Department of Urology, New York University Cancer Institute, Kaplan Comprehensive Cancer Center, New York, New York, USA. Iman.Osman@med.nyu.edu
authors.forename: Iman
authors.initials: I
authors.lastname: Osman
authors.forename: Herman
authors.initials: H
authors.lastname: Yee
authors.forename: Samir S
authors.initials: SS
authors.lastname: Taneja
authors.forename: Benjamin
authors.initials: B
authors.lastname: Levinson
authors.forename: Anne
authors.initials: A
authors.lastname: Zeleniuch-Jacquotte
authors.forename: Caroline
authors.initials: C
authors.lastname: Chang
authors.forename: Craig
authors.initials: C
authors.lastname: Nobert
authors.forename: David M
authors.initials: DM
authors.lastname: Nanus
mesh_terms: D019175:DNA Methylation; D018450:Disease Progression; D015536:Down-Regulation; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D015999:Multivariate Analysis; D015260:Neprilysin / Q000096:biosynthesis* / Q000378:metabolism; D011379:Prognosis; D011401:Promoter Regions, Genetic; D017430:Prostate-Specific Antigen / Q000096:biosynthesis / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000201:enzymology* / Q000473:pathology
chemical_list: D017430:Prostate-Specific Antigen; D015260:Neprilysin